会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • STATIC AIR MIXING APPARATUS
    • 静态混合装置
    • WO1996019702A1
    • 1996-06-27
    • PCT/US1995015294
    • 1995-11-21
    • BLENDER PRODUCTS, INC.ROBINSON, Keith, D.ERICKSON, Thomas, A.
    • BLENDER PRODUCTS, INC.
    • F24F13/04
    • B01F5/064B01F5/0602B01F5/0682F24F13/04
    • An improved static air mixing apparatus (30) is disclosed which includes an inner enclosure (34) at least partially traversing a duct (31), an outer enclosure (36) surrounding the inner enclosure (34), a first plurality of radial vanes (38) extending outwardly from a center of the inner enclosure (34) to adjacent the inner enclosure (34), a second plurality of radial vanes (40) extending from between the inner and outer enclosures (34, 36), and a transition member (42) forming a divergent retention region downstream of the enclosures (34, 36) for prolonging mixing of different temperature airstreams as they pass through the air mixing apparatus (30). Further improvements are derived from an optimized depth ratio between the depth of the enclosures to the minimum diameter of the outer enclosure of between .37 and .40 and core ratio between the core area defined by the inner enclosure (34) to the outer enclosure (36) area including the core area of between about .60 to about .65.
    • 公开了一种改进的静态空气混合设备(30),其包括至少部分地穿过管道(31)的内部外壳(34),围绕内部外壳(34)的外部外壳(36),第一多个径向叶片 从所述内壳体(34)的中心向外延伸到邻近所述内壳体(34)的第二多个径向叶片(40),所述第二多个径向叶片(40)从所述内壳体和外壳体(34,36)之间延伸,以及过渡构件 (42),在所述外壳(34,36)的下游形成发散的保留区域,用于在不同温度的气流通过所述空气混合装置(30)时延长混合。 进一步的改进来自于外壳的深度与外壳的最小直径之间的优化的深度比在.37和.40之间以及由内壳(34)与外壳(34)限定的芯区之间的芯比 36)区域,核心区域约在.60到.65之间。
    • 7. 发明申请
    • THERAPEUTIC AGENTS
    • 治疗药剂
    • WO1991002724A1
    • 1991-03-07
    • PCT/EP1990001376
    • 1990-08-17
    • THE BOOTS COMPANY PLCDAVIES, Roy, VictorROBINSON, Keith
    • THE BOOTS COMPANY PLC
    • C07D215/36
    • C07D215/36
    • Compounds of formula (I), in which R is lower alkyl; R is lower alkyl; R is halogenated lower alkoxy, halogenated lower alkylthio, halogenated lower alkylsulphinyl or halogenated lower alkylsulphonyl; R and R , which may be the same or different, are hydrogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, halo, halogenated lower alkyl, halogenated lower alkoxy, halogenated lower alkylthio, halogenated lower alkylsulphinyl, halogenated lower alkylsulphonyl, cyano, phenyl or phenyl substituted by 1 to 3, especially 1 or 2, groups selected from lower alkyl, lower alkoxy, halo or halogenated lower alkyl; m is 0 or 1; and n is 0, 1 or 2, have antihypertensive activity. Processes for preparing compounds of formula (I) and pharmaceutical compositions containing them are described.
    • 式(I)化合物,其中R 1是低级烷基; R 2是低级烷基; R 3是卤代低级烷氧基,卤代低级烷硫基,卤代低级烷基亚磺酰基或卤代低级烷基磺酰基; R 4和R 5可以相同或不同,为氢,低级烷基,低级烷氧基,低级烷硫基,低级烷基亚磺酰基,低级烷基磺酰基,卤素,卤代低级烷基,卤代低级烷氧基,卤代低级烷硫基, 卤代低级烷基亚磺酰基,卤代低级烷基磺酰基,氰基,苯基或被1至3,特别是1或2个选自低级烷基,低级烷氧基,卤代或卤代低级烷基的基团取代的苯基; m为0或1; 和n为0,1或2,具有抗高血压活性。 描述了制备式(I)化合物和含有它们的药物组合物的方法。